Bionano Genomics Inc

Bionano Genomics operates with a highly leveraged capital structure, evidenced by a price-to-book ratio of 0.29 and a tangible book ratio of 0.29, both significantly below the industry median. The company's liquidity position is constrained by negative free cash flow of -$16.59 million and operating cash flow of -$16.35 million, despite holding $2.99 million in cash and equivalents. The current ratio of 1.98 suggests short-term obligations are covered, but the negative net cash position after subtracting total debt raises liquidity concerns. Profitability metrics show severe underperformance relative to industry norms. The company reported a net loss of $26.40 million on $28.51 million in revenue, resulting in a negative return on equity of -59.42% and return on assets of -35.87%. Gross margin of 46.26% (calculated from $13.19 million gross profit) is strong, but operating losses of $33.34 million indicate significant overhead and R&D expenses. These results fall well below the industry's median profitability metrics. Geographic and segment exposure is opaque in the provided data, but the company's revenue concentration appears limited to its core genomic analysis systems business. No material geographic breakdown is disclosed, and the absence of segment reporting suggests a single-product focus. This lack of diversification increases vulnerability to market-specific disruptions. The company's growth trajectory is negative, with no revenue growth data provided and a current FY outlook showing continued losses. The operating income of -$33.34 million and net income of -$26.40 million indicate a deteriorating financial position. Analysts have assigned a mean price target of $5.00, implying a 324% upside from the current market price of $1.18, but the absence of buy recommendations (only 2 "buy" and 1 "hold") suggests limited institutional confidence. Risk factors include high liquidity risk due to negative free cash flow and operating cash flow, as well as a negative net cash position. The dilution risk is currently low, with no near-term pressure indicated by the unchanged basic and diluted share counts of 11.09 million. However, the company's capital structure adjustments (e.g., equity raises) could introduce dilution risk in the future. Recent events include the publication of 10-K filings and investor presentations highlighting the company's Saphyr genomic analysis system. No material earnings transcripts or regulatory actions are disclosed in the provided data. The absence of capital expenditures ($0.00) suggests the company is not investing in physical infrastructure, potentially relying on R&D for growth.